Search results for "Germany."

showing 10 items of 1165 documents

Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers …

2018

To support a fully liquid, diphtheria (D)-tetanus (T)-acellular pertussis (aP)-inactivated poliovirus (IPV)-hepatitis B (HB)-Haemophilus influenzae b (PRP-T) vaccine in Europe using a 2, 3, 4 month primary series and a booster at 11-15 months of age. Phase III, randomized, observer-blind studies in Germany and the Czech Republic. Participants who had not received HB vaccine were randomized to a 2, 3, 4 month primary series of DTaP-IPV-HB-PRP-T (group 1; N = 266) or a reconstituted DTaP-HB-IPV//PRP-T comparator (group 2; N = 263) and a booster of the same vaccine. Pneumococcal vaccine (PCV13) and rotavirus vaccine were coadministered at 2, 3, 4 months, and the booster was coadministered with…

0301 basic medicineMicrobiology (medical)MalePediatricsmedicine.medical_specialty030106 microbiologyImmunization SecondaryBooster doseAntibodies ViralDiphtheria-Tetanus-acellular Pertussis Vaccines03 medical and health sciences0302 clinical medicineImmunogenicity VaccineSuspensionsGermanyTetanus ToxoidMedicineHumansHepatitis B Vaccines030212 general & internal medicineVaccines CombinedDiphtheria-Tetanus-acellular Pertussis VaccinesImmunization ScheduleCzech RepublicHaemophilus VaccinesBooster (rocketry)business.industryDiphtheriaImmunogenicityVaccinationInfant NewbornInfantmedicine.diseaseRotavirus vaccineAntibodies BacterialVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesPneumococcal vaccinePediatrics Perinatology and Child HealthFemalebusinessThe Pediatric infectious disease journal
researchProduct

mRCC Outcome in the Treatment of Metastatic Renal Cell Carcinoma - A German Single-center Real-world Experience.

2018

Background/Aim: Since the advent of targeted therapeutics, paradigms in metastatic renal cell carcinoma (mRCC) treatment have changed. We investigated if efficacy and safety data from randomized controlled trials can be transferred into real-world settings. Patients and Methods: All patients with mRCC treated from 2006-2015 at the Department of Urology (Marburg-Germany) were retrospectively analyzed. Collected data include: Patient demographics, tumor characteristics, efficacy, safety, and used therapy sequences. Results: In total, 197 patients with mRCC were identified. About one third of patients reached third-line therapy. Median overall survival in real-world amounted to 25.8 months wit…

0301 basic medicineOncologyAdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentSingle CenterGeneral Biochemistry Genetics and Molecular BiologyTyrosine-kinase inhibitorTargeted therapylaw.invention03 medical and health sciences0302 clinical medicineRisk groupsRandomized controlled trialRenal cell carcinomalawRisk FactorsInternal medicineGermanymedicineOverall survivalHumansMolecular Targeted TherapyNeoplasm MetastasisSurvival rateCarcinoma Renal CellProtein Kinase InhibitorsAgedRandomized Controlled Trials as TopicRetrospective StudiesPharmacologybusiness.industryNeoplasms Second PrimaryMiddle Agedmedicine.diseaseProgression-Free Survival030104 developmental biologyTreatment Outcome030220 oncology & carcinogenesisFemalebusinessResearch ArticleIn vivo (Athens, Greece)
researchProduct

Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With L…

2020

Contains fulltext : 220040.pdf (Publisher’s version ) (Closed access) BACKGROUND & AIMS: Lynch syndrome is caused by variants in DNA mismatch repair (MMR) genes and associated with an increased risk of colorectal cancer (CRC). In patients with Lynch syndrome, CRCs can develop via different pathways. We studied associations between Lynch syndrome-associated variants in MMR genes and risks of adenoma and CRC and somatic mutations in APC and CTNNB1 in tumors in an international cohort of patients. METHODS: We combined clinical and molecular data from 3 studies. We obtained clinical data from 2747 patients with Lynch syndrome associated with variants in MLH1, MSH2, or MSH6 from Germany, the Net…

0301 basic medicineOncologyMaleColorectal cancerDNA Mutational Analysisgenetic analysisHEREDITARYcancer riskGUIDELINESDNA Mismatch Repair0302 clinical medicineGermanyTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]Prospective Studiesprognostic factorFinlandbeta CateninNetherlandsOutcomePrognostic FactorGastroenterologyGenetic AnalysisColonoscopyMiddle AgedCANCERLynch syndromeCancer Risk3. Good healthDNA-Binding ProteinsDEFICIENCYMutS Homolog 2 Proteinsyöpägeenitoutcome030211 gastroenterology & hepatologyDNA mismatch repairFemaleMutL Protein Homolog 1geenitutkimusAdenomaAdultmedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesAdenoma3122 CancersAdenomatous Polyposis Coli ProteinINSTABILITYSOCIETYMLH103 medical and health sciencesInternal medicinemedicineMANAGEMENTHumansLynchin oireyhtymäneoplasmspaksusuolisyöpäHepatologybusiness.industryCancernutritional and metabolic diseasesennusteetmedicine.diseaseColorectal Neoplasms Hereditary Nonpolyposisdigestive system diseasesMSH6030104 developmental biologyMSH2Mutationbusiness
researchProduct

Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study.

2019

Lymph node ratio (LNR) can predict treatment outcome and prognosis in patients with solid tumors. Aim of the present analysis was to confirm the concept of using LNR for assessing outcome in patients with vulvar cancer after surgery with inguinal lymphadenectomy in a large multicenter project.The AGO-CaRE-1 study multicenter database was used for analysis. LNR was defined as ratio of number of positive lymph nodes (LN) to the number of resected. Previously established LNR risk groups were used to stratify patients. LNR was investigated with respect to clinical parameters. Univariate and multivariable survival analyses were performed to assess the value of LNR in order to predict overall (OS…

0301 basic medicineOncologyMalemedicine.medical_specialtyMedizinInguinal lymphadenectomyRisk AssessmentVulva03 medical and health sciences0302 clinical medicineRisk groupsPredictive Value of TestsInternal medicineNodal statusGermanymedicineHumansIn patientLymph nodeAgedNeoplasm StagingRetrospective StudiesVulvar Neoplasmsbusiness.industryObstetrics and GynecologyVulvar cancerMiddle Agedmedicine.diseasePrognosisSurvival Analysis030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisLymphatic MetastasisCarcinoma Squamous CellLymph Node ExcisionFemaleLymphLymph NodesbusinessGynecologic oncology
researchProduct

Current practice in nutrition after allogeneic hematopoietic stem cell transplantation – Results from a survey among hematopoietic stem cell transpla…

2021

Summary Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) is frequently associated with impaired oral intake and malnutrition, which potentially increases morbidity and mortality. Therefore, nutrition is one of the major challenges in the post-transplant period. Methods To document the current clinical approach in nutritional treatment, we designed a questionnaire concerning the current practice in nutrition after alloHSCT and distributed it to German speaking centers performing alloHSCT in Germany, Austria and Switzerland between November 2018 and March 2020. Twenty-eight (39%) of 72 contacted centers completed the survey, 23 from Germany, two from Austria and three …

0301 basic medicineParenteral Nutritionmedicine.medical_specialtyConsensusNeutropeniamedicine.medical_treatment030209 endocrinology & metabolismHematopoietic stem cell transplantationCritical Care and Intensive Care MedicineNutrition PolicyEating03 medical and health sciences0302 clinical medicineQuality of lifeGermanyInternal medicinemedicineVitamin D and neurologyHumansPractice Patterns Physicians'030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryBody WeightMalnutritionHematopoietic Stem Cell Transplantationmedicine.diseaseMicronutrientComorbidityDietMalnutritionParenteral nutritionGraft-versus-host diseaseAustriaHealth Care SurveysDietary SupplementsbusinessSwitzerlandClinical Nutrition
researchProduct

Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes

2016

International audience; Evidence from a small number of studies suggests that longer telomere length measured in peripheral leukocytes is associated with an increased risk of non-Hodgkin lymphoma (NHL). However, these studies may be biased by reverse causation, confounded by unmeasured environmental exposures and might miss time points for which prospective telomere measurement would best reveal a relationship between telomere length and NHL risk. We performed an analysis of genetically inferred telomere length and NHL risk in a study of 10 102 NHL cases of the four most common B-cell histologic types and 9562 controls using a genetic risk score (GRS) comprising nine telomere length-associa…

0301 basic medicineSerumMaleLymphomaanalysisChronic lymphocytic leukemiaFollicular lymphomaGlobal Health[ SDV.CAN ] Life Sciences [q-bio]/Cancerimmunologysurgery0302 clinical medicineEndocrinologyimmune system diseasessingle nucleotide polymorphismGermanyhemic and lymphatic diseasesLondon80 and overOdds RatiogeneticsProspective StudiesB-cell lymphomaAssociation Studies ArticleGenetics (clinical)Aged 80 and overeducation.field_of_studytelomereGenomeLeukemiaAge FactorsGeneral MedicineEnvironmental exposureGenomicsMiddle Agedb-cell lymphomasmall cell lymphomaItaly030220 oncology & carcinogenesisMedicineepidemiologyFemaleFranceRisk of B-cell lymphoma subtypesRiskAdultCanadaChinaLymphoma B-CellGenotypeAdolescentleukocytesetiologyPopulationPopulation[SDV.CAN]Life Sciences [q-bio]/CancerBiologyEnvironmentRisk AssessmentmethodsTime03 medical and health sciencesmedicineHumansFamilyGenetic Predisposition to DiseaseeducationMolecular BiologyAllelesOccupational HealthGenetic Association StudiesAgedB-CellInternational AgenciesOdds ratioEnvironmental Exposuremedicine.diseaseTelomereNon-Hodgkin's lymphoma030104 developmental biologyImmunologyphysiologyChronic DiseasepathologyLaboratoriesmetabolism
researchProduct

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placeb…

2018

Summary Background Antiangiogenic therapy has known activity in ovarian cancer. The investigator-initiated randomised phase 2 TRIAS trial assessed the multi-kinase inhibitor sorafenib combined with topotecan and continued as maintenance therapy for platinum-resistant or platinum-refractory ovarian cancer. Methods We did a multicentre, double-blind, placebo-controlled, randomised, phase 2 trial at 20 sites in Germany. Patients (≥18 years) with platinum-resistant ovarian cancer previously treated with two or fewer chemotherapy lines for recurrent disease were stratified (first vs later relapse) in block sizes of four and randomly assigned (1:1) using a web-generated response system to topotec…

0301 basic medicineSorafenibAdultmedicine.medical_specialtyTime FactorsPerforation (oil well)Angiogenesis InhibitorsPlatinum CompoundsNeutropeniaPlaceboGastroenterologyDrug Administration Schedule03 medical and health sciences0302 clinical medicineMaintenance therapyDouble-Blind MethodInternal medicineGermanyAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansProgression-free survivalProtein Kinase InhibitorsAgedOvarian Neoplasmsbusiness.industryMiddle AgedSorafenibmedicine.diseaseProgression-Free Survival030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisDisease ProgressionTopotecanFemaleTopoisomerase I InhibitorsbusinessTopotecanmedicine.drugThe Lancet. Oncology
researchProduct

Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter …

2020

ABSTRACT Resection of colorectal liver metastases (CRLM) is a potential curative treatment for patients with metastatic colorectal cancer (mCRC) with liver-limited disease (LLD). Although long-term survival improved considerably within the last decades, high recurrence rates of 50-75% after resection remain a major challenge.Tecemotide (L-BLP25) is an antigen-specific cancer vaccine inducing immunity against mucin-1 (MUC1). The LICC trial aimed to improve survival in patients with mCRC after R0/R1 resection of CRLM. LICC was a binational, randomized, double-blind, placebo-controlled, multicenter phase 2 study including patients with R0/R1 resected CRLM without evidence of metastatic disease…

0301 basic medicinemedicine.medical_specialtyLung Neoplasmsmucin-1 (muc1)Colorectal cancermedicine.medical_treatmentImmunologyMedizinPlaceboCancer VaccinesGastroenterologyResectionDouble blind03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungGermanyInternal medicinemedicineHumansImmunology and AllergyRC254-282Original ResearchMembrane Glycoproteinsresection of colorectal liver metastasesbusiness.industryLiver NeoplasmsVaccinationNeoplasms. Tumors. Oncology. Including cancer and carcinogenscolorectal neoplasmsRC581-607medicine.diseasedigestive system diseasesVaccination030104 developmental biologyOncologyCurative treatment030220 oncology & carcinogenesistecemotide (l-blp25)TecemotideNeoplasm Recurrence LocalImmunologic diseases. AllergybusinessAdjuvantResearch Articleliver-limited diseaseOncoImmunology
researchProduct

Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies

2021

Virotherapy research involves the development, exploration, and application of oncolytic viruses that combine direct killing of cancer cells by viral infection, replication, and spread (oncolysis) with indirect killing by induction of anti-tumor immune responses. Oncolytic viruses can also be engineered to genetically deliver therapeutic proteins for direct or indirect cancer cell killing. In this review—as part of the special edition on “State-of-the-Art Viral Vector Gene Therapy in Germany”—the German community of virotherapists provides an overview of their recent research activities that cover endeavors from screening and engineering viruses as oncolytic cancer therapeutics to their cli…

0301 basic medicinemedicine.medical_treatmentGenetic enhancementvirus targetingMedizinReviewcombination therapychemistry.chemical_compoundDDC 570 / Life sciencesClinical trials0302 clinical medicineKlinisches ExperimentGermanyNeoplasmsMedicineimmunotherapy ; therapeutic transgene ; combination therapy ; Virustherapie ; clinical trials ; virus engineering ; oncolytic virus ; research in Germany ; virus targeting ; virotherapyOncolytic VirotherapyClinical Trials as Topicvirus engineeringKombinationstherapieQR1-5023. Good healthOncolytic VirusesInfectious Diseases030220 oncology & carcinogenesisImmunotherapyvirotherapyGenetic Engineeringresearch in GermanyMicrobiologyVirusViral vector03 medical and health sciencesImmune systemddc:570VirologyAnimalsHumanstherapeutic transgeneVirotherapyoncolytic virusbusiness.industryImmunotherapyVirologyOncolytic virusImmuntherapie030104 developmental biologychemistryVacciniabusinessViruses
researchProduct

Supplemented ERA-EDTA Registry data evaluated the frequency of dialysis, kidney transplantation, and comprehensive conservative management for patien…

2021

The aims of this study were to determine the frequency of dialysis and kidney transplantation and to estimate the regularity of comprehensive conservative management (CCM) for patients with kidney failure in Europe. This study uses data from the ERA-EDTA Registry. Additionally, our study included supplemental data from Armenia, Germany, Hungary, Ireland, Kosovo, Luxembourg, Malta, Moldova, Montenegro, Slovenia and additional data from Israel, Italy, Slovakia using other information sources. Through an online survey, responding nephrologists estimated the frequency of CCM (i.e. planned holistic care instead of kidney replacement therapy) in 33 countries. In 2016, the overall incidence of rep…

0301 basic medicinemedicine.medical_treatment[SDV]Life Sciences [q-bio]030232 urology & nephrologyConservative TreatmentDISEASE0302 clinical medicineGermanyMedicine and Health SciencesRegistriesRenal InsufficiencyKidney transplantationeducation.field_of_studyhemodialysisGreeceRENAL REPLACEMENT THERAPY3. Good healthEuropeperitoneal dialysisItalyNephrologyHemodialysismedicine.medical_specialtyPopulationhemodialysis [Keywords]Peritoneal dialysis03 medical and health sciencesRenal DialysisInternal medicinemedicineHumansRenal replacement therapyeducationDialysisEdetic AcidPortugalbusiness.industryHome hemodialysisCAREmedicine.disease3126 Surgery anesthesiology intensive care radiologyKidney TransplantationTransplantation030104 developmental biologySpainKidney Failure ChronicDONATIONbusinessIrelandtransplantationKidney international
researchProduct